BIOC
He tomado una pequeña participación en esta nano-farma (capitaliza $40M) que ha desarrollado una "biopsia líquida" para el cáncer de pulmón...
http://finance.yahoo.com/news/biocept-liquid-biopsy-lung-cancer-110000380.html
...viene de bastante arriba (52wk-range: 1.09 - 4.91), así que el precio de entrada (2.20) no me parece disparatado. Espero que me vaya mejor que con mis últimas compras corto-plazistas.
PPHM
Sigues dentro? Rompe la bajista de corto plazo con gap de escape, buen movimiento y news:
New Translational Data Highlights Bavituximab's Ability to Induce Signs of Immune Activation in Lung Cancer Tumor Samples With Negative PD-L1 Expression
Results from the study are being presented as part of a mini-oral presentation at the International Association for the Study of Lung Cancer's (IASLC's) World Conference on Lung Cancer (WCLC), being held this week in Denver, Colorado.
http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=930479
DMPI arrancando.....
+15,89%....
30,9k títulos negociados.....
DMPI
ATNM
Pathwin, que se nos calienta la bicha! O ya te saliste? El jueves hay una conferencia (creo que después del cierre).
DATE: Thursday, September 10, 2015
TIME: 1 pm ET
LINK: http://tinyurl.com/sep10pre
This will be a live, interactive online event where investors are invited to ask the company questions in real-time – both in the presentation hall as well as the association’s “virtual trade booth.” If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days.
It is recommended that investors pre-register to save time and receive event updates.
Selected Recent Company Highlights
Enrollment began and first patient has been treated in ADRESU Japanese urinary incontinence approval trial
Cytori began enrollment and first patient has been treated in US Phase III/pivotal scleroderma STAR trial
Cytori announced Japanese approval trial for Stress Urinary Incontinence using Cytori Cell Therapy
Cytori reported its Licensee, Kerastem Technologies, received conditional approval from FDA for a Phase II Alopecia Trial
Cytori completed enrollment of US Phase IIb Osteoarthritis Trial, ACT-OA trial, 6-month data expected in Q1 2016
Celution processed adipose derived cell therapy was granted orphan drug status for treatment of scleroderma in European Union
Cytori reported positive topline 12-month follow-up data on SCLERADEC-I Trial
Cytori and Lorem Vascular were granted regulatory clearance for Cytori Celution® System by the State Food and Drug Administration of the People’s Republic of China , and initial purchase order placed by Lorem Vascular
CYTX
http://www.4-traders.com/CYTORI-THERAPEUTICS-INC-8997/consensus/
Bastante movimiento últimamente en la empresa, tiene un precio objetivo medio de 4 $ pero me conformo con que alcance los 1$ . Saludos
ATNM
Ahí sigo con todas, está la llevo ahora con +14. Me esta jodiendo un poco el cambio €/$.
Sólo llevó en rojo ahora OCAT (se nos ha vuelto a desinflar) y CYTX
Company Update (NASDAQ:INO): Inovio Pharmaceuticals Inc Announces First Patient Dosed With Universal HIV Vaccine
INO
Tras la new de la dilucion, cuanto mas sube MNKD mas ganas me entran de meterle un corto ...
